Characterization of Cannabinoid Receptors
互联网
- Abstract
- Table of Contents
- Materials
- Figures
- Literature Cited
Abstract
This unit describes the use of cannabinoid radioligands in competitive binding assays for determining affinity parameters (IC50 , K i ) of unlabeled compounds at transfected CB1 and CB2 receptors expressed in cell lines. Curr. Protoc. Pharmacol . 63:1.26.1?1.26.10. © 2013 by John Wiley & Sons, Inc.
Keywords: cannabinoids; receptor binding; GPR 55
Table of Contents
- Reagents and Solutions
- Commentary
- Literature Cited
- Figures
- Tables
Materials
Basic Protocol 1:
Materials
|
Figures
-
Figure 1.26.1 Competition binding curves demonstrating inhibition of [3 H]CP 55,940 binding to the human CB1 receptor by competition with unlabeled WIN 55,212‐2, HU‐210, and CP 55,940. Data from Table were fit using GraphPad Prism software. View Image
Videos
Literature Cited
Ashton, J.C. 2012. The atypical cannabinoid O‐1602: Targets, actions, and the central nervous system. Cent. Nerv. Syst. Agents Med. Chem. 12:233‐239. | |
Aung, M.M., Griffin, G., Huffman, J.W., Wu, M.‐J., Keel, M., Yang, B., Showalter, V.M., Abood, M.E., and Martin, B.R. 2000. Influence of the N‐1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend. 60:133‐140. | |
Baker, D., Pryce, G., Davies, W.L., and Hiley, C.R. 2006. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27:1‐4. | |
Breivogel, C.S. and Childers, S.R. 2000. Cannabinoid agonist signal transduction in rat brain: Comparison of cannabinoid agonists in receptor binding, G‐protein activation and adenylyl cyclase inhibition. J. Pharm. Exp. Therap. 295:328‐336. | |
Cheng, Y.‐C. and Prusoff, W.H. 1973. Relationship between the inhibition constant (Kl) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099‐3103. | |
Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulan, R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946‐1949. | |
Fattore, L. and Fratta, W. 2011. Beyond THC: The new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 5:60. | |
Hanus, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R.G., Ross, R.A., and Mechoulam, R. 1999. HU‐308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A. 96:14228‐14233. | |
Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., and Pertwee, R.G. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54:161‐202. | |
Iversen, L.L. 2000. The Science of Marijuana, Oxford University Press, Oxford, United Kingdom. | |
Iversen, L.L. 2003. Cannabis and the brain. Brain 126:1252‐1270. | |
Kearn, C.S., Greenberg, M.J., DiCamelli, R., Kurzawa, K., and Hillard, C.J. 1999. Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem. 72:2379‐2387. | |
Kumar, R.N., Chambers, W.A., and Pertwee, R.G. 2001. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 56:1059‐1068. | |
Lan, R., Liu, Q., Fan, P., Gatley, J., Volkow, N.D., Fernando, S.R., Pertwee, R.G., and Makriyannis, A. 1999. Structure‐activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42:769‐776. | |
Lange, J.H., Coolen, H.K., van Stuivenberg, H.H., Dijksman, J.A., Herremans, A.H., Ronken, E., Keizer, H.G., Tipker, K., McCreary, A.C., Veerman, W., Wals, H.C., Stork, B., Verveer, P.C., den Hartog, A.P., de Jong, N.M., Adolfs, T.J., Hoogendoorn, J., and Kruse, C.G. 2004. Synthesis, biological properties, and molecular modeling investigations of novel 3,4‐diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J. Med. Chem. 47:627‐643. | |
Luft, F.C. 2013. Rehabilitating rimonabant. J. Mol. Med. 91:777‐779. | |
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561‐564. | |
McHugh, D., Hu, S.S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J.M., and Bradshaw, H.B. 2010. N‐arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 11:44. | |
McHugh, D., Page, J., Dunn, E., and Bradshaw, H.B. 2012. Δ(9)‐Tetrahydrocannabinol and N‐arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC‐1B cells. Br. J. Pharmacol. 165:2414‐2424. | |
Munro, S., Thomas, K.L., and Abu‐shaar, M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61‐65. | |
Pertwee, R.G. 1999. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:635‐664. | |
Pertwee, R.G. 2010. Cannabinoid Receptor Ligands. Tocris Reviews No. 27. http://www.tocris.com/pdfs/pdf_downloads/Cannabinoid_Receptor_Ligands_Review.pdf. | |
Pertwee, R.G., Howlett, A.C., Abood, M., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Cravatt, B.F., Devane, W.A., Elphick, M.R., Felder, C.C., Herkenham, M., Kunos, G., Mackie, K., Martin, B.R., and Mechoulam, R. 2011. Cannabinoid receptors, introductory chapter. IUPHAR database (IUPHAR‐DB). http://www.iuphar‐db.org/DATABASE/FamilyIntroductionForward ?familyId=13. | |
Sharir, H. and Abood, M.E. 2010 Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Therap. 126:301‐313. | |
Thomas, B.F., Gilliam, A.F., Burch, D.F., Roche, M.J., and Seltzman, H.H. 1997. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharm. Exp. Therap. 285:285‐292. | |
Velasco, G., Sánchez, C., and Guzmán, M. 2012. Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer 12:436‐444. | |
Yao B.B., Mukherjee, S., Fan, Y., Garrison, T.R., Daza, A.V., Grayson, H.K., Hooker, B.A., Dart, M.J., Sullivan, J.P., and Meyer, M.D. 2006 In vitro pharmacological characterization of AM1241: A protean agonist at the cannabinoid CB2 receptor? Br. J. Pharmacol. 149:145‐154. | |
Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D.G., Caldwell, J.S., and Chen, Y.A. 2009. Lipid G protein‐coupled receptor ligand identification using β‐arrestin PathHunter assay. J. Biol. Chem. 284:12328‐12338. | |
Key References | |
Pertwee, R.G. 2010. See above. | |
Contains up to date summary tables of Kd and Ki values for cannabinoid ligands. | |
Internet Resources | |
http://www.iuphar‐db.org/index.jsp | |
IUPHAR Committee on Receptor Nomenclature and Drug Classification. IUPAR Database. | |
http://www.graphpad.com | |
A key resource on cannabinoid receptors. | |
http://www.cannabinoidsociety.org | |
Contains a data analysis resource center covering receptor binding theory and data analysis. The online radioactivity calculator is particularly useful. |